Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GW597599 + ondansetron
- Development stage
- Phase 2
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
GW597599 + ondansetron is a combination drug consisting of GW597599 (a code name for an experimental compound, details of which are limited and not provided in the search results) and ondansetron, a selective serotonin 5-HT3 receptor antagonist widely used for the prevention and treatment of nausea and vomiting induced by chemotherapy, radiotherapy, or surgery. In such combinations, each agent acts via its specific mechanism—ondansetron antagonizes the 5-HT3 receptor primarily peripherally at vagal nerve terminals and centrally in the area postrema, preventing emesis, while GW597599’s exact mechanism is unspecified in accessible literature. The combination drug is presumably being explored for enhanced or broader-spectrum antiemetic efficacy.
- Brand names
- ZofranZuplenz
02
Targets
HTR3A (5-hydroxytryptamine receptor 3A)TACR1 (Neurokinin‑1 Receptor)
Beyond the preview
Go deeper on GW597599 + ondansetron.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GW597599 + ondansetron.